A phase I study to evaluate safety, immunogenicity and antitumor activity of a HER2 multi-peptide virosome vaccine in patients with metastatic breast cancer

Christoph Wiltschke,Ursula Wiedermann,R. Zurbriggen,Katarzyna Elandt,Kira H. Brämswig,Joanna Jasinska,Hubert Pehamberger,Otto Scheiner,Christoph Zielinski

A phase I study to evaluate safety, immunogenicity and antitumor activity of a HER2 multi-peptide virosome vaccine in patients with metastatic breast cancer

2008

Christoph Wiltschke
Ursula Wiedermann
R. Zurbriggen
Katarzyna Elandt
Kira H. Brämswig
Joanna Jasinska
Hubert Pehamberger
Otto Scheiner
Christoph Zielinski

3055 Background: Anti-HER2 directed immunotherapy has proven to be beneficial in patients with HER2 overexpressing breast cancer. This makes HER2 an attractive target for a therapeutic vaccine. We ...

Keywords:

Virosome
Immunogenicity
Cancer research
Pathology
Metastatic breast cancer
Peptide
Medicine
Internal medicine
antitumor activity
Breast cancer
Oncology
in patient
Immunotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations